Drug Profile


Alternative Names: REV 3988; RG 3988; RHC 3988

Latest Information Update: 11 Aug 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action Cell membrane modulators; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic rhinitis; Asthma
  • Discontinued Peptic ulcer

Most Recent Events

  • 11 Aug 1997 No-Development-Reported for Allergic rhinitis (PO)
  • 11 Aug 1997 No-Development-Reported for Asthma in USA (PO)
  • 19 Sep 1994 Discontinued - Unspecified phase in Allergic rhinitis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top